Should I buy or sell UCB stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for UCB in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" UCBJY shares. View UCBJY analyst ratings or view top-rated stocks .

How have UCBJY shares performed in 2024?

UCB's stock was trading at $43.60 at the start of the year. Since then, UCBJY shares have increased by 44.5% and is now trading at $63.00. View the best growth stocks for 2024 here .

Are investors shorting UCB?

UCB saw a decrease in short interest in the month of March. As of March 31st, there was short interest totaling 200 shares, a decrease of 71.4% from the March 15th total of 700 shares. Based on an average daily trading volume, of 13,300 shares, the short-interest ratio is currently 0.0 days. View UCB's Short Interest .

How often does UCB pay dividends? What is the dividend yield for UCB?

UCB announced a dividend on Wednesday, April 26th. Investors of record on Tuesday, May 2nd will be given a dividend of $0.4583 per share on Thursday, May 18th. This represents a dividend yield of 0.95%. The ex-dividend date is Monday, May 1st. This is an increase from the stock's previous dividend of $0.44. Read our dividend analysis for UCBJY .

Is UCB a good dividend stock?

UCB (OTCMKTS:UCBJY) pays an annual dividend of $0.36 per share and currently has a dividend yield of 1.26%. The dividend payout ratio is 46.55%. This payout ratio is at a healthy, sustainable level, below 75%. Read our dividend analysis for UCBJY .

How do I buy shares of UCB?

Shares of UCBJY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

OTCMKTS:UCBJY

UCB (UCBJY) Stock Price, News & Analysis

→ Forget Nvidia, buy this A.I. Stock Now (From InvestorPlace) (Ad)

Free UCBJY Stock Alerts

$63.00

-0.87 (-1.36%)

(As of 04/15/2024 ET)

Compare

Today's Range: $62.83
▼
$63.64
50-Day Range: $46.76
▼
$63.87
52-Week Range: $34.85
▼
$65.00

Volume: 10,776 shs
Average Volume: 11,674 shs
Market Capitalization: N/A

P/E Ratio: 82.52
Dividend Yield: 0.56%
Price Target: N/A

Stock Analysis Analyst Forecasts Chart Dividend Financials SEC Filings Short Interest

Get UCB alerts:

Ad InvestorPlace

REVEALED: Elon Musk’s Secret A.I. Facility?

I recently shot this video outside what could be Elon Musk’s biggest secret. What’s happening inside these walls is so important that our government has declared it a matter of national security.

Click here to see the details because there’s a lot of money at stake.

About UCB Stock (OTCMKTS:UCBJY)

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; Bimzelx for treating plaque psoriasis, psoriatic arthritis, and axial spondyloarthritis; and Fintepla to treat Dravet syndrome. In addition, the company is involved in developing rozanolixizumab and Zilbrisq to treat myasthenia gravis; dapirolizumab pegol for systemic lupus erythematosus; fenfluramine to treat CDKL5 deficiency disorder; doxecitine for TK2 deficiency disorder; STACCATO alprazolam for stereotypical prolonged seizures; bepranemab to treat Alzheimer's disease; minzasolmin and UCB0222 for Parkinson's disease; and UCB1381 and UCB9741 for atropic dermatitis. Further, it engages in contract manufacturing activities. UCB SA has collaboration agreements with Amgen, Biogen, Roche/Genentech, Novartis, and Otsuka. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.

UCBJY Stock Price History

30 days | 90 days | 365 days | Advanced Chart

UCBJY Stock News Headlines

December 29, 2023 | seekingalpha.com

Drugmakers reportedly planning to raise prices on 500+ drugs in January (update)

December 29, 2023 | msn.com

Drugmakers reportedly planning to raise prices on 500+ drugs in January

April 16, 2024 | InvestorPlace (Ad)

“Forget Tesla, this is Elon’s Next Big Thing”

According to Forbes, this breakthrough could define the future of AI. Most people don’t know about it… Because it was found 750 miles away from Silicon Valley.

December 28, 2023 | msn.com

FDA’s new drug approvals for 2023 rise 51% from last year

December 1, 2023 | finance.yahoo.com

UCB presents new data advancing patient-focused scientific leadership at American Epilepsy Society Annual Meeting

November 14, 2023 | finance.yahoo.com

UCB Announces U.S. Availability of BIMZELX® for the Treatment of Adults with Moderate-to-Severe Plaque Psoriasis

October 18, 2023 | msn.com

FDA approves UCB's Bimzelx for plaque psoriasis

October 4, 2023 | benzinga.com

UCB presents late-breaking posters at Child Neurology Society Meeting

April 16, 2024 | InvestorPlace (Ad)

“Forget Tesla, this is Elon’s Next Big Thing”

According to Forbes, this breakthrough could define the future of AI. Most people don’t know about it… Because it was found 750 miles away from Silicon Valley.

September 15, 2023 | msn.com

EMA advisors recommend many new meds at latest meeting

August 31, 2023 | markets.businessinsider.com

Skin Disease Focused MoonLake Immunotherapeutics Poised To Outshine Rivals, Analyst Asserts

August 26, 2023 | msn.com

Crohn's disease drugmakers set to benefit from expected rise in cases

April 13, 2023 | msn.com

UCB (UCBJY) Declares $0.73 Dividend

April 6, 2023 | wsj.com

United Commercial Bank Ltd.

March 20, 2023 | benzinga.com

Bimekizumab Phase 3 Data in Hidradenitis Suppurativa Show Clinically Meaningful, Deep and Maintained Response over 48 Weeks

December 23, 2022 | finance.yahoo.com

UCB SA (UCBJY) Stock Historical Prices & Data - Yahoo Finance

December 9, 2022 | seekingalpha.com

UCB drug meets main goals of 2 phase 3 trials for painful skin disorder

November 8, 2022 | benzinga.com

UCB Reinforces Commitment to Rheumatology With 15 Abstracts Including New Late-Breaking Data at ACR Convergence 2022

September 24, 2022 | benzinga.com

UCB presents latest data from generalized myasthenia gravis portfolio at AANEM meeting

September 22, 2022 | finance.yahoo.com

UCB SA (UCB.BR)

September 17, 2022 | reuters.com

UCB.BR - UCB SA | Stock Price & Latest News | Reuters

September 2, 2022 | benzinga.com

UCB Showcases Strength of the Expanding Dermatology Portfolio at the 31st EADV Congress

May 11, 2022 | finance.yahoo.com

UCB presents efficacy and safety results for zilucoplan and rozanolixizumab in generalized myasthenia gravis

May 4, 2022 | markets.businessinsider.com

JAMA Neurology Publishes Phase 3 Study Results on the Efficacy and Safety of FINTEPLA® (fenfluramine) Oral Solution in Lennox-Gastaut Syndrome (LGS)

March 29, 2022 | markets.businessinsider.com

FINTEPLA® (fenfluramine) Oral Solution Now FDA Approved for Treatment of Seizures Associated with Lennox-Gastaut Syndrome (LGS)

March 28, 2022 | finance.yahoo.com

UCB's Rare Childhood Epilepsy Drug Scores FDA Approval

March 28, 2022 | seekingalpha.com

UCB's Fintepla gets FDA approval to treat rare childhood epilepsy

See More Headlines

Receive UCBJY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for UCB and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Sector: Medical
Industry: Biotechnology
Sub-Industry: N/A
Current Symbol: OTCMKTS:UCBJY
CUSIP: N/A
CIK: 1290640
Web: www.ucb.com
Phone: (322) 559-9999
Fax: N/A
Employees: 8,450
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: 82.52
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: N/A
Free Float: N/A
Market Cap: N/A
Optionable: Not Optionable
Beta: N/A

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

Mr. Jean-Christophe Tellier (Age 65)
CEO & Executive Director
Comp: $4.45M
Ms. Sandrine Dufour CFA (Age 58)
Executive VP, CFO & Chief Corporate Development
Dr. Kirsten Lund-Jurgensen Ph.D. (Age 64)
Executive Vice President of Supply & Technology Solutions
Dr. Dhavalkumar D. Patel M.D. (Age 63)
Ph.D., Executive VP & Chief Scientific Officer
Ms. Denelle J. Waynick Johnson J.D. (Age 57)
Executive VP & General Counsel
Mr. Jean-Luc Fleurial (Age 59)
Executive VP & Chief Human Resources Officer
Prof. Iris Low-Friedrich (Age 64)
Executive VP & Chief Medical Officer
Mr. Emmanuel Caeymaex (Age 55)
Executive VP of Immunology Solutions & Head of US
Ms. Caroline Vancoillie
Chief Accounting Officer, Head of Group Finance & CFO of Patient Value Functions
Antje Witte
Head of Investor Relations

Key Competitors

View All Competitors

UCBJY Stock Analysis - Frequently Asked Questions

Should I buy or sell UCB stock right now?: 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for UCB in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" UCBJY shares.
View UCBJY analyst ratings or view top-rated stocks.
How have UCBJY shares performed in 2024?: UCB's stock was trading at $43.60 at the start of the year. Since then, UCBJY shares have increased by 44.5% and is now trading at $63.00.
View the best growth stocks for 2024 here.
Are investors shorting UCB?: UCB saw a decrease in short interest in the month of March. As of March 31st, there was short interest totaling 200 shares, a decrease of 71.4% from the March 15th total of 700 shares. Based on an average daily trading volume, of 13,300 shares, the short-interest ratio is currently 0.0 days.
View UCB's Short Interest.
How often does UCB pay dividends? What is the dividend yield for UCB?: UCB announced a dividend on Wednesday, April 26th. Investors of record on Tuesday, May 2nd will be given a dividend of $0.4583 per share on Thursday, May 18th. This represents a dividend yield of 0.95%. The ex-dividend date is Monday, May 1st. This is an increase from the stock's previous dividend of $0.44.
Read our dividend analysis for UCBJY.

Is UCB a good dividend stock?: UCB (OTCMKTS:UCBJY) pays an annual dividend of $0.36 per share and currently has a dividend yield of 1.26%. The dividend payout ratio is 46.55%. This payout ratio is at a healthy, sustainable level, below 75%.
Read our dividend analysis for UCBJY.
How do I buy shares of UCB?: Shares of UCBJY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:UCBJY) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial